CLINICAL TRIALS PROFILE FOR NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE
✉ Email this page to a colleague
All Clinical Trials for NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00007592 ↗ | Hypertension Screening and Treatment Program | Completed | US Department of Veterans Affairs | 1989-06-01 | Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension. | |
NCT00007592 ↗ | Hypertension Screening and Treatment Program | Completed | VA Office of Research and Development | 1989-06-01 | Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension. | |
NCT00093925 ↗ | Clevidipine in the Postoperative Treatment of Hypertension (ECLIPSE-NIC) | Completed | The Medicines Company | Phase 3 | 2004-05-01 | The purpose of this study is to establish the safety of clevidipine in the treatment of postoperative hypertension. Approximately 250-500 patients with postoperative hypertension after undergoing coronary artery bypass grafting (CABG), off-pump coronary artery bypass (OPCAB) or minimally invasive direct coronary artery bypass (MIDCAB) surgery and/or valve replacement/repair procedures were anticipated to be randomly assigned to one of two treatment groups: clevidipine or nicardipine. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE
Condition Name
Clinical Trial Locations for NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE
Trials by Country
Clinical Trial Progress for NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE
Sponsor Name